Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 44fludarabine phosphate 40Busulfan 32Tacrolimus 27Filgrastim 26Methotrexate 24Cytarabine 24Cyclosporine 23Antilymphocyte Serum 22Radiotherapy 20Mycophenolic Acid 19Whole-Body Irradiation 18Etoposide 18Imatinib Mesylate 17Methylprednisolone 15Melphalan 13Cord Blood Stem Cell Transplantation 10sargramostim 9Thiotepa 9fludarabine 8Psychiatric Rehabilitation 8Dasatinib 8Topotecan 7Therapeutics 7Prednisone 7Flow Cytometry 7Carboplatin 7merphos 6Decitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Blast Crisis × troxacitabine × Clear all
NCT00012259 2021-06-10

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Takeda

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡